<DOC>
	<DOC>NCT02149160</DOC>
	<brief_summary>The purposes of this study are to investigate the safety, tolerability, and pharmacodynamics of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin mutation.</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia, Primary Progressive</mesh_term>
	<mesh_term>Pick Disease of the Brain</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Male or female ages aged ≥21 and ≤75 years Genotyped positive for a FTDGRN mutation, and aware of it Prodromal to moderate FTDGRN Resides in a stable living situation, living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24hour) nursing care Proficiency (oral and written) in the language in which studyrelated documents, including the ICF and standardized tests, will be administered Able to swallow capsules Be in good general health, willing and able to comply with the protocol requirements, and expected to complete the study as designed (in the judgment of the investigator) Clinically significant abnormalities on physical examination, medical history, ECG, vital signs, laboratory values, or unstable medical or psychiatric illness Females who are pregnant, breastfeeding, or planning to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>Frontotemporal dementia</keyword>
	<keyword>Granulin</keyword>
</DOC>